Results 221 to 230 of about 1,006,148 (403)

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Blood, 2017
E. Stein, C. Dinardo, D. Pollyea, A. Fathi, G. Roboz, J. Altman, R. Stone, D. DeAngelo, R. Levine, I. Flinn, H. Kantarjian, R. Collins, M. Patel, A. Frankel, A. Stein, M. Sekeres, R. Swords, B. Medeiros, C. Willekens, P. Vyas, A. Tosolini, Qiang Xu, R. Knight, K. Yen, S. Agresta, S. de Botton, M. Tallman   +26 more
semanticscholar   +1 more source

Up-Regulation of P21 Inhibits TRAIL-Mediated Extrinsic Apoptosis, Contributing Resistance to SAHA in Acute Myeloid Leukemia Cells [PDF]

, 2014
Xing Wu, Na Yang, Wei-hua Zhou, Jie Xu, Jia-Jie Chen, Fei-Meng Zheng, Zi-Jie Long, Cai-feng Yue, Ke-xin Ai, Ling-Ling Liu, Xian-Yao Wan, Quentin Liu   +11 more
openalex   +1 more source

Cytokine pathways driving diverse tissue pathologies in rheumatoid arthritis

Arthritis &Rheumatology, Accepted Article.
Rheumatoid arthritis is a complex systemic disorder characterised primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease e.g. of the lung with potentially devastating clinical consequences.
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

LncRNA SNHG11 expression in acute myeloid leukemia patients and its relationship with the biology of acute myeloid leukemia cells. [PDF]

Clin Exp Med
Sun K, Zhou J, Yao H, Jiao P, Zhang R, Wang G.   +5 more
europepmc   +1 more source

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

New England Journal of Medicine, 2003
S. O’Brien, F. Guilhot, R. Larson, I. Gathmann, M. Baccarani, F. Cervantes, J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner, J. L. Nielsen, P. Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simonsson, A. Gratwohl, J. Goldman, H. Kantarjian, K. Taylor, G. Verhoef, A. Bolton, R. Capdeville, B. Druker   +24 more
semanticscholar   +1 more source

Polyomavirus Enhancer-binding Protein 2/Core Binding Factor/Acute Myeloid Leukemia Factors Contribute to the Cell Type-specific Activity of the CD11a Integrin Gene Promoter [PDF]

, 2000
Amaya Puig‐Kröger, Cristina López-Rodrı́guez, Miguel Relloso, Tilman Sánchez-Elsner, Arsenio Nueda, Eduardo Muñóz, Carmelo Bernabéu, Ángel L. Corbí   +7 more
openalex   +1 more source

Dysregulation of U12‐Type Splicing in Lupus Neutrophils

Arthritis &Rheumatology, Accepted Article.
Abstract. Objective Neutrophil dysfunction is a hallmark of systemic lupus erythematosus (SLE), but its molecular basis remains unclear. This study explores transcriptional and post‐transcriptional changes in low‐density granulocytes (LDGs), a proinflammatory neutrophil subset expanded in SLE, focusing on NADPH oxidase (Nox) function and minor intron ...
Luz P. Blanco, Binod Regmi, Carmelo Carmona‐Rivera, Yudong Liu, Xiantao Wang, Philip M. Carlucci, Monica M. Jackson, Zerai Manna, Sarfaraz Hasni, Markus Hafner, Hong‐Wei Sun, Mariana J. Kaplan   +11 more
wiley   +1 more source

ELK1 promotes the progress of myeloid leukemia by hindering the differentiation of neutrophils. [PDF]

Exp Hematol Oncol
He Y, Zhou Y, Wen D, Guo R, Du J, Huang S, Dong Y.   +6 more
europepmc   +1 more source

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.

, 2023
Andreas Hochhaus, Andreas Burchert, Susanne Saußele, Gabriela M. Baerlocher, Jiřı́ Mayer, Tim H. Brümmendorf, Paul La Rosée, Dominik Heim, Stefan W. Krause, Philipp le Coutre, Christian Fabisch, Jenny Rinke, Thoralf Lange, Alice Fabarius, Marcel Lorch, Mathias Hänel, Frank Stegelmann, Georg‐Nikolaus Franke, Markus P. Radsak, Volker Kunzmann, Danny Himsel, Denise Kohn, Thomas Lang, Rüdiger Hehlmann, Thomas Ernst, Markus Pfirrmann   +25 more
openalex   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source